Cotadutide trims weight, improves liver markers in T2D patients with NAFLD
04 Sep 2020
byJairia Dela Cruz
In the treatment of patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), the first-in-class GLP-1/glucagon dual-receptor agonist cotadutide confers positive effects on body weight, alanine aminotransferase levels, and markers of liver fat and fibrosis, although these benefits appear to come with adverse gastrointestinal events, as shown in a phase IIb study.
